AbbVie Says Humira's Many Patents Is No Antitrust Violation

By Matt Bernardini (October 15, 2019, 5:37 PM EDT) -- AbbVie and several other drugmakers have asked an Illinois federal court to dismiss a sweeping proposed class action accusing the company of illegally shielding its immunosuppressant Humira from competition with a "patent thicket," saying there is no limit to how many patents a company can hold.

The complaint accuses AbbVie Inc. of violating antitrust laws by amassing more than 100 patents to keep biosimilar versions of Humira off the U.S. market until 2023. It also names seven other biosimilar makers as defendants and accuses them of agreeing to carve up markets with AbbVie to allow biosimilar sales in Europe but delay those...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!